David Blum

List of Publications by Year
in descending order

149 papers	9,413 citations	34016 52 h-index	42291 92 g-index
156 all docs	156 docs citations	156 times ranked	11803 citing authors

#	Article	IF	Citations
1	Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Progress in Neurobiology, 2001, 65, 135-172.	2.8	1,056
2	NLRP3 inflammasome activation drives tau pathology. Nature, 2019, 575, 669-673.	13.7	782
3	3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. Journal of Neurochemistry, 2005, 95, 1521-1540.	2.1	327
4	Tau and neuroinflammation: What impact for Alzheimer's Disease and Tauopathies?. Biomedical Journal, 2018, 41, 21-33.	1.4	262
5	Biochemistry of Tau in Alzheimerâ€™s disease and related neurological disorders. Expert Review of Proteomics, 2008, 5, 207-224.	1.3	242
6	Tau Phosphorylation and Sevoflurane Anesthesia. Anesthesiology, 2012, 116, 779-787.	1.3	195
7	Hippocampal T cell infiltration promotes neuroinflammation and cognitive decline in a mouse model of tauopathy. Brain, 2017, 140, 184-200.	3.7	184
8	Novel Alzheimer risk genes determine the microglia response to amyloidâ€Î² but not to TAU pathology. EMBO Molecular Medicine, 2020, 12, e10606.	3.3	182
9	Targeting Phospho-Ser422 by Active Tau Immunotherapy in the THYTau22 Mouse Model: A Suitable Therapeutic Approach. Current Alzheimer Research, 2012, 9, 397-405.	0.7	173
10	Beneficial effects of caffeine in a transgenic model of Alzheimer's disease-like tau pathology. Neurobiology of Aging, 2014, 35, 2079-2090.	1.5	163
11	Tau deletion promotes brain insulin resistance. Journal of Experimental Medicine, 2017, 214, 2257-2269.	4.2	158
12	Atypical, non-standard functions of the microtubule associated Tau protein. Acta Neuropathologica Communications, 2017, 5, 91.	2.4	157
13	Neurotoxicity and Memory Deficits Induced by Soluble Low-Molecular-Weight Amyloid-Â1-42 Oligomers Are Revealed In Vivo by Using a Novel Animal Model. Journal of Neuroscience, 2012, 32, 7852-7861.	1.7	156
14	Clinical potential of minocycline for neurodegenerative disorders. Neurobiology of Disease, 2004, 17, 359-366.	2.1	145
15	A2A adenosine receptor deletion is protective in a mouse model of Tauopathy. Molecular Psychiatry, 2016, 21, 97-107.	4.1	145
16	Beneficial effects of exercise in a transgenic mouse model of Alzheimer's disease-like Tau pathology. Neurobiology of Disease, 2011, 43, 486-494.	2.1	137
17	Adenosine receptors and Huntington's disease: implications for pathogenesis and therapeutics. Lancet Neurology, The, 2003, 2, 366-374.	4.9	129
18	Age-related shift in LTD is dependent on neuronal adenosine A2A receptors interplay with mGluR5 and NMDA receptors. Molecular Psychiatry, 2020, 25, 1876-1900.	4.1	129

#	Article	IF	Citations
19	Premature ovarian aging in mice deficient for Gpr3. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 8922-8926.	3.3	128
20	Altered Neuronal Excitability in Cerebellar Granule Cells of Mice Lacking Calretinin. Journal of Neuroscience, 2003, 23, 9320-9327.	1.7	122
21	A Dual Role of Adenosine A_{2A}Receptors in 3-Nitropropionic Acid-Induced Striatal Lesions: Implications for the Neuroprotective Potential of A_{2A}Antagonists. Journal of Neuroscience, 2003, 23, 5361-5369.	1.7	118
22	Cognition and hippocampal synaptic plasticity in mice with a homozygous tau deletion. Neurobiology of Aging, 2014, 35, 2474-2478.	1.5	116
23	Hypothalamic Alterations in Neurodegenerative Diseases and Their Relation to Abnormal Energy Metabolism. Frontiers in Molecular Neuroscience, 2018, 11, 2.	1.4	113
24	p53 and Bax activation in 6-hydroxydopamine-induced apoptosis in PC12 cells. Brain Research, 1997, 751, 139-142.	1.1	104
25	Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington's disease. Progress in Neurobiology, 2007, 81, 331-348.	2.8	102
26	The Chemokine MIP-1Î±/CCL3 impairs mouse hippocampal synaptic transmission, plasticity and memory. Scientific Reports, 2015, 5, 15862.	1.6	100
27	Role of the Tau N-terminal region in microtubule stabilization revealed by newendogenous truncated forms. Scientific Reports, 2015, 5, 9659.	1.6	100
28	Cholesterol 24-hydroxylase defect is implicated in memory impairments associated with Alzheimer-like Tau pathology. Human Molecular Genetics, 2015, 24, 5965-5976.	1.4	96
29	Extracellular toxicity of 6-hydroxydopamine on PC12 cells. Neuroscience Letters, 2000, 283, 193-196.	1.0	93
30	Hippocampal tauopathy in tau transgenic mice coincides with impaired hippocampus-dependent learning and memory, and attenuated late-phase long-term depression of synaptic transmission. Neurobiology of Learning and Memory, 2011, 95, 296-304.	1.0	93
31	The Peptidylprolyl cis/trans-Isomerase Pin1 Modulates Stress-induced Dephosphorylation of Tau in Neurons. Journal of Biological Chemistry, 2006, 281, 19296-19304.	1.6	89
32	Detrimental Effects of Diet-Induced Obesity on Ï„ Pathology Are Independent of Insulin Resistance in Ï„ Transgenic Mice. Diabetes, 2013, 62, 1681-1688.	0.3	88
33	IL-17 triggers the onset of cognitive and synaptic deficits in early stages of Alzheimerâ€™s disease. Cell Reports, 2021, 36, 109574.	2.9	88
34	From tau phosphorylation to tau aggregation: what about neuronal death?. Biochemical Society Transactions, 2010, 38, 967-972.	1.6	87
35	Dysregulation of TrkB Receptors and BDNF Function by Amyloid-Î² Peptide is Mediated by Calpain. Cerebral Cortex, 2015, 25, 3107-3121.	1.6	84
36	D-Î²-Hydroxybutyrate Is Protective in Mouse Models of Huntington's Disease. PLoS ONE, 2011, 6, e24620.	1.1	81

#	Article	IF	Citations
37	Deregulation of neuronal miRNAs induced by amyloid-Î² or TAU pathology. Molecular Neurodegeneration, 2018, 13, 54.	4.4	80
38	Effects of the Adenosine A2A Receptor Antagonist SCH 58621 on Cyclooxygenase-2 Expression, Glial Activation, and Brain-Derived Neurotrophic Factor Availability in a Rat Model of Striatal Neurodegeneration. Journal of Neuropathology and Experimental Neurology, 2007, 66, 363-371.	0.9	78
39	Stem cell factor and mesenchymal and neural stem cell transplantation in a rat model of Huntington's disease. Molecular and Cellular Neurosciences, 2008, 37, 454-470.	1.0	76
40	A genetic variation in the ADORA2A gene modifies age at onset in Huntington's disease. Neurobiology of Disease, 2009, 35, 474-476.	2.1	75
41	Mutant huntingtin alters Tau phosphorylation and subcellular distribution. Human Molecular Genetics, 2015, 24, 76-85.	1.4	73
42	The Adenosine A₁Receptor Agonist Adenosine Amine Congener Exerts a Neuroprotective Effect against the Development of Striatal Lesions and Motor Impairments in the 3-Nitropropionic Acid Model of Neurotoxicity. Journal of Neuroscience, 2002, 22, 9122-9133.	1.7	72
43	Beneficial Effect of a Selective Adenosine A2A Receptor Antagonist in the APPswe/PS1dE9 Mouse Model of Alzheimerâ€™s Disease. Frontiers in Molecular Neuroscience, 2018, 11, 235.	1.4	72
44	Exacerbation of C1q dysregulation, synaptic loss and memory deficits in tau pathology linked to neuronal adenosine A2A receptor. Brain, 2019, 142, 3636-3654.	3.7	71
45	NMDA receptor dysfunction contributes to impaired brainâ€derived neurotrophic factorâ€induced facilitation of hippocampal synaptic transmission in a <scp>T</scp>au transgenic model. Aging Cell, 2013, 12, 11-23.	3.0	64
46	A Critical Evaluation of Adenosine A2A Receptors as Potentially “Druggable” Targets in Huntingtons Disease. Current Pharmaceutical Design, 2008, 14, 1500-1511.	0.9	63
47	Association between caffeine intake and age at onset in Huntington's disease. Neurobiology of Disease, 2013, 58, 179-182.	2.1	63
48	Effects of Remifentanil on NÂ-methyl-d-aspartate Receptor. Anesthesiology, 2005, 102, 1235-1241.	1.3	61
49	Reinstating plasticity and memory in a tauopathy mouse model with an acetyltransferase activator. EMBO Molecular Medicine, 2018, 10, .	3.3	61
50	Worsening of Huntington disease phenotype in CB1 receptor knockout mice. Neurobiology of Disease, 2011, 42, 524-529.	2.1	56
51	Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 552-555.	0.9	55
52	The caffeine-binding adenosine A2A receptor induces age-like HPA-axis dysfunction by targeting glucocorticoid receptor function. Scientific Reports, 2016, 6, 31493.	1.6	55
53	Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system. Transfusion Medicine, 2010, 20, 48-61.	0.5	53
54	Death of cortical and striatal neurons induced by mitochondrial defect involves differential molecular mechanisms. Neurobiology of Disease, 2004, 15, 152-159.	2.1	52

#	Article	IF	Citations
55	Minocycline in phenotypic models of Huntington's disease. Neurobiology of Disease, 2005, 18, 206-217.	2.1	52
56	Early Tau Pathology Involving the Septo-Hippocampal Pathway in a Tau Transgenic Model: Relevance to Alzheimers Disease. Current Alzheimer Research, 2009, 6, 152-157.	0.7	50
57	Topological analysis of striatal lesions induced by 3-nitropropionic acid in the Lewis rat. NeuroReport, 2001, 12, 1769-1772.	0.6	47
58	Striatal and Cortical Neurochemical Changes Induced by Chronic Metabolic Compromise in the 3-Nitropropionic Model of Huntington's Disease. Neurobiology of Disease, 2002, 10, 410-426.	2.1	47
59	Controlled delivery of glial cell line-derived neurotrophic factor by a single tetracycline-inducible AAV vector. Experimental Neurology, 2007, 204, 387-399.	2.0	47
60	Adenosine Augmentation Evoked by an ENT1 Inhibitor Improves Memory Impairment and Neuronal Plasticity in the APP/PS1 Mouse Model of Alzheimerâ€™s Disease. Molecular Neurobiology, 2018, 55, 8936-8952.	1.9	46
61	Thyroid Hormone Supplementation Restores Spatial Memory, Hippocampal Markers of Neuroinflammation, Plasticity-Related Signaling Molecules, and Î²-Amyloid Peptide Load in Hypothyroid Rats. Molecular Neurobiology, 2019, 56, 722-735.	1.9	46
62	PTUâ€induced hypothyroidism in rats leads to several early neuropathological signs of Alzheimer's disease in the hippocampus and spatial memory impairments. Hippocampus, 2014, 24, 1381-1393.	0.9	45
63	From epidemiology to pathophysiology: what about caffeine in Alzheimer's disease?. Biochemical Society Transactions, 2014, 42, 587-592.	1.6	45
64	Central Nervous System and Peripheral Inflammatory Processes in Alzheimerâ€™s Disease: Biomarker Profiling Approach. Frontiers in Neurology, 2015, 6, 181.	1.1	44
65	A2A receptor knockout worsens survival and motor behaviour in a transgenic mouse model of Huntington's disease. Neurobiology of Disease, 2011, 41, 570-576.	2.1	43
66	Unlike MPP+, apoptosis induced by 6-OHDA in PC12 cells is independent of mitochondrial inhibition. Neuroscience Letters, 1996, 221, 69-71.	1.0	42
67	6-hydroxydopamine-induced nuclear factor-kappaB activation in PC12 cells22Abbreviations: 6-OHDA, 6-hydroxydopamine; EMSA, electrophoretic mobility shift assay; GSH, glutathione; IAP, inhibitory apoptosis protein; MAP, mitogen-activated protein; NAC, N-acetyl-cystein; NF-Î°B, nuclear factor-Î°B; and PD, Parkinsonâ€™s disease.. Biochemical Pharmacology, 2001, 62, 473-481.	2.0	40
68	Nuclear factor-Î°B activation in permanent intraluminal focal cerebral ischemia in the rat. Neuroscience Letters, 2000, 288, 241-245.	1.0	38
69	Loss of Medial Septum Cholinergic Neurons in THY-Tau22 Mouse Model: What Links with tau Pathology?. Current Alzheimer Research, 2011, 8, 633-638.	0.7	38
70	Progressive Age-Related Cognitive Decline in Tau Mice. Journal of Alzheimer's Disease, 2013, 37, 777-788.	1.2	38
71	Neuroprotective effect of zVAD against the neurotoxin 3-nitropropionic acid involves inhibition of calpain. Neuropharmacology, 2005, 49, 695-702.	2.0	37
72	Rescue of impaired lateâ€“phase long-term depression in a tau transgenic mouse model. Neurobiology of Aging, 2015, 36, 730-739.	1.5	37

#	Article	IF	Citations
73	Increased tauopathy drives microglia-mediated clearance of beta-amyloid. Acta Neuropathologica Communications, 2016, 4, 63.	2.4	35
74	The Role of Adenosine Tone and Adenosine Receptors in Huntington's Disease. Journal of Caffeine and Adenosine Research, 2018, 8, 43-58.	0.8	35
75	The Adenosinergic Signaling: A Complex but Promising Therapeutic Target for Alzheimerâ€™s Disease. Frontiers in Neuroscience, 2018, 12, 520.	1.4	34
76	Amyloid and Tau Neuropathology Differentially Affect Prefrontal Synaptic Plasticity and Cognitive Performance in Mouse Models of Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 37, 109-125.	1.2	32
77	Filamin-A and Myosin VI colocalize with fibrillary Tau protein in Alzheimer's disease and FTDP-17 brains. Brain Research, 2010, 1345, 182-189.	1.1	28
78	Human platelet concentrates: a source of solvent/detergentâ€treated highly enriched brainâ€derived neurotrophic factor. Transfusion, 2012, 52, 1721-1728.	0.8	28
79	A 2A Râ€induced transcriptional deregulation in astrocytes: An in vitro study. Glia, 2019, 67, 2329-2342.	2.5	28
80	Mutual Relationship between Tau and Central Insulin Signalling: Consequences for AD and Tauopathies?. Neuroendocrinology, 2018, 107, 181-195.	1.2	27
81	Neuronal tau species transfer to astrocytes and induce their loss according to tau aggregation state. Brain, 2021, 144, 1167-1182.	3.7	27
82	P2X7-deficiency improves plasticity and cognitive abilities in a mouse model of Tauopathy. Progress in Neurobiology, 2021, 206, 102139.	2.8	23
83	Lack of Minocycline Efficiency in Genetic Models of Huntington's Disease. NeuroMolecular Medicine, 2007, 9, 47-54.	1.8	22
84	Association of corticobasal degeneration and Huntington's disease: Can Tau aggregates protect Huntingtin toxicity?. Movement Disorders, 2009, 24, 1089-1090.	2.2	22
85	Tacrolimus-induced nephrotoxicity in mice is associated with microRNA deregulation. Archives of Toxicology, 2018, 92, 1539-1550.	1.9	22
86	Caffeine intake exerts dual genome-wide effects on hippocampal metabolism and learning-dependent transcription. Journal of Clinical Investigation, 2022, 132, .	3.9	22
87	Increased Alix (apoptosis-linked gene-2 interacting protein X) immunoreactivity in the degenerating striatum of rats chronically treated by 3-nitropropionic acid. Neuroscience Letters, 2004, 368, 309-313.	1.0	21
88	New piperazine multi-effect drugs prevent neurofibrillary degeneration and amyloid deposition, and preserve memory in animal models of Alzheimer's disease. Neurobiology of Disease, 2019, 129, 217-233.	2.1	21
89	Human platelet lysate biotherapy for traumatic brain injury: preclinical assessment. Brain, 2021, 144, 3142-3158.	3.7	21
90	Observations in THY-Tau22 mice that resemble behavioral and psychological signs and symptoms of dementia. Behavioural Brain Research, 2013, 242, 34-39.	1.2	20

#	Article	IF	Citations
91	The neuroprotective activity of heat-treated human platelet lysate biomaterials manufactured from outdated pathogen-reduced (amotosalen/UVA) platelet concentrates. Journal of Biomedical Science, 2019, 26, 89.	2.6	20
92	Glial cells and adaptive immunity in frontotemporal dementia with tau pathology. Brain, 2021, 144, 724-745.	3.7	19
93	Heat-treated human platelet pellet lysate modulates microglia activation, favors wound healing and promotes neuronal differentiation in vitro. Platelets, 2021, 32, 226-237.	1.1	17
94	Glial Purinergic Signaling in Neurodegeneration. Frontiers in Neurology, 2021, 12, 654850.	1.1	17
95	Characterization and Chromatographic Isolation of Platelet Extracellular Vesicles from Human Platelet Lysates for Applications in Neuroregenerative Medicine. ACS Biomaterials Science and Engineering, 2021, 7, 5823-5835.	2.6	17
96	Clearance of manganese from the rat substantia nigra following intra-nigral microinjections. Neuroscience Letters, 2002, 328, 170-174.	1.0	16
97	Tau pathology modulates Pin1 post-translational modifications and may be relevant as biomarker. Neurobiology of Aging, 2013, 34, 757-769.	1.5	16
98	Aging, but not tau pathology, impacts olfactory performances and somatostatin systems in THY-Tau22 mice. Neurobiology of Aging, 2015, 36, 1013-1028.	1.5	16
99	Dual role of MUC1 mucin in kidney ischemia-reperfusion injury: Nephroprotector in early phase, but pro-fibrotic in late phase. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 1336-1349.	1.8	16
100	Brain insulin response and peripheral metabolic changes in a Tau transgenic mouse model. Neurobiology of Disease, 2019, 125, 14-22.	2.1	16
101	Minocycline-induced activation of tetracycline-responsive promoter. Neuroscience Letters, 2003, 352, 155-158.	1.0	15
102	Novel Lipidized Analog of Prolactin-Releasing Peptide Improves Memory Impairment and Attenuates Hyperphosphorylation of Tau Protein in a Mouse Model of Tauopathy. Journal of Alzheimer's Disease, 2018, 62, 1725-1736.	1.2	15
103	Caffeine Consumption During Pregnancy Accelerates the Development of Cognitive Deficits in Offspring in a Model of Tauopathy. Frontiers in Cellular Neuroscience, 2019, 13, 438.	1.8	15
104	Brain network remodelling reflects tau-related pathology prior to memory deficits in Thy-Tau22 mice. Brain, 2020, 143, 3748-3762.	3.7	15
105	THY-Tau22 mouse model accumulates more tauopathy at late stage of the disease in response to microglia deactivation through TREM2 deficiency. Neurobiology of Disease, 2021, 155, 105398.	2.1	14
106	Early-Life Environment Influence on Late-Onset Alzheimerâ€™s Disease. Frontiers in Cell and Developmental Biology, 2022, 10, 834661.	1.8	14
107	Hippocampal BDNF Expression in a Tau Transgenic Mouse Model. Current Alzheimer Research, 2012, 9, 406-410.	0.7	12
108	Chronic intoxication with 3-nitropropionic acid in rats induces the loss of striatal dopamine terminals without affecting nigral cell viability. Neuroscience Letters, 2004, 354, 234-238.	1.0	11

#	Article	IF	Citations
109	Hyperexcitability and seizures in the THY-Tau22 mouse model of tauopathy. Neurobiology of Aging, 2020, 94, 265-270.	1.5	11
110	Design, synthesis and evaluation of 2-aryl benzoxazoles as promising hit for the A_{2A}receptor. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 850-864.	2.5	10
111	Omics analysis of mouse brain models of human diseases. Gene, 2017, 600, 90-100.	1.0	10
112	Chronic Sodium Selenate Treatment Restores Deficits in Cognition and Synaptic Plasticity in a Murine Model of Tauopathy. Frontiers in Molecular Neuroscience, 2020, 13, 570223.	1.4	10
113	Myotonic Dystrophy: an RNA Toxic Gain of Function Tauopathy?. Advances in Experimental Medicine and Biology, 2019, 1184, 207-216.	0.8	10
114	Equilibrative nucleoside transporter 1 inhibition rescues energy dysfunction and pathology in a model of tauopathy. Acta Neuropathologica Communications, 2021, 9, 112.	2.4	8
115	Increased surface P2X4 receptors by mutant SOD1 proteins contribute to ALS pathogenesis in SOD1-G93A mice. Cellular and Molecular Life Sciences, 2022, 79, .	2.4	8
116	The Controversial Role of Adenosine A2A Receptor Antagonists as Neuro-protective Agents. Current Medicinal Chemistry - Central Nervous System Agents, 2004, 4, 35-45.	0.6	7
117	Does physical activity associated with chronic food restriction alleviate anxiety like behaviour, in female mice?. Hormones and Behavior, 2020, 124, 104807.	1.0	7
118	Recombinant AAV Viral Vectors Serotype 1, 2, and 5 Mediate Differential Gene Transfer Efficiency in Rat Striatal Fetal Grafts. Cell Transplantation, 2007, 16, 1013-1020.	1.2	6
119	Alzheimerâ€™s disease risk, obesity and tau: is insulin resistance guilty?. Expert Review of Neurotherapeutics, 2013, 13, 461-463.	1.4	6
120	Consensus Brain-derived Protein, Extraction Protocol for the Study of Human and Murine Brain Proteome Using Both 2D-DIGE and Mini 2DE Immunoblotting. Journal of Visualized Experiments, 2014, , .	0.2	6
121	Can the administration of platelet lysates to the brain help treat neurological disorders?. Cellular and Molecular Life Sciences, 2022, 79, .	2.4	6
122	Tau Protein: Function and Pathology. International Journal of Alzheimer's Disease, 2012, 2012, 1-2.	1.1	5
123	mRNA Levels of ACh-Related Enzymes in the Hippocampus of THY-Tau22 Mouse: A Model of Human Tauopathy with No Signs of Motor Disturbance. Journal of Molecular Neuroscience, 2016, 58, 411-415.	1.1	5
124	Tau, Diabetes and Insulin. Advances in Experimental Medicine and Biology, 2019, 1184, 259-287.	0.8	5
125	Neuroprotective activity of a virusâ€safe nanofiltered human platelet lysate depleted of extracellular vesicles in Parkinson's disease and traumatic brain injury models. Bioengineering and Translational Medicine, 2023, 8, .	3.9	5
126	Stabilizing synapses. Science, 2021, 374, 684-685.	6.0	4

#	Article	IF	Citations
127	Impaired Glucose Homeostasis in a Tau Knock-In Mouse Model. Frontiers in Molecular Neuroscience, 2022, 15, 841892.	1.4	4
128	Mort neuronale dans les modÃ¨les expÃ©rimentaux de la maladie de Parkinson. Medecine/Sciences, 2002, 18, 457-466.	0.0	3
129	Citicoline is not protective in experimental models of Huntington's disease. Neurobiology of Aging, 2007, 28, 1944-1946.	1.5	3
130	Design and synthesis of fused tetrahydroisoquinoline-iminoimidazolines. European Journal of Medicinal Chemistry, 2015, 106, 15-25.	2.6	3
131	Editorial: Purinergic Signaling in Health and Disease. Frontiers in Cellular Neuroscience, 2020, 14, 15.	1.8	3
132	Impact of chronic doxycycline treatment in the APP/PS1 mouse model of Alzheimer's disease. Neuropharmacology, 2022, 209, 108999.	2.0	3
133	Mammalian Brain Ca2+ Channel Activity Transplanted into Xenopus laevis Oocytes. Membranes, 2022, 12, 496.	1.4	3
134	Calpain-2 Mediates MBNL2 Degradation and a Developmental RNA Processing Program in Neurodegeneration. Journal of Neuroscience, 2022, 42, 5102-5114.	1.7	3
135	A cautionary note on the use of stable transformed cells. Apoptosis: an International Journal on Programmed Cell Death, 2000, 5, 115-116.	2.2	2
136	Adenosine Receptors and Alzheimerâ€™s Disease. , 2013, , 385-407.		2
137	What Is the Role of Adenosine Tone and Adenosine Receptors in Huntingtonâ€™s Disease?. , 2018, , 281-308.		2
138	A ÃŸ-Secretase Modulator Decreases Tau Pathology and Preserves Short-Term Memory in a Mouse Model of Neurofibrillary Degeneration. Frontiers in Pharmacology, 2021, 12, 679335.	1.6	2
139	RLU and studies using the luciferase reporter gene. Nature Biotechnology, 1998, 16, 702-702.	9.4	1
140	In situ examination of tyrosine hydroxylase activity in the rat locus coeruleus using (3?,5?)-[3H2]-?-fluoromethyl-tyrosine as substrate of the enzyme. , 2000, 35, 201-211.		1
141	Minocycline-induced activation of tetracycline-responsive promoter. Neuroscience Letters, 2003, , .	1.0	1
142	Overexpression of mouse IsK protein fused to green fluorescent protein induces apoptosis of human astroglioma cells. Neurological Research, 2007, 29, 628-631.	0.6	1
143	C08â€…Caffeine is a modifier of age at onset in Huntington's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, A18.2-A18.	0.9	1
144	Adenosine Receptors in Huntingtonâ€™s Disease. , 2013, , 409-434.		1

#	Article	IF	Citations
145	Mycoplasmas as gene therapy vectors?. Nature Biotechnology, 1999, 17, 4-4.	9.4	0
146	Adenosine Receptors and Memory Disorders. , 2017, , 175-186.		0
147	Adenosine: A Complex Role in Neurodegeneration. Journal of Caffeine and Adenosine Research, 2019, 9, 71-72.	0.8	0
148	Tau- but not AÃŸ -pathology enhances NMDAR-dependent depotentiation in AD-mouse models. Acta Neuropathologica Communications, 2019, 7, 202.	2.4	0
149	Uncovering bidirectional brain-body interactions in health and disease. Neuropharmacology, 2022, 212, 109073.	2.0	0